Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | DAO | P14920 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20562948 | 0.98 | ALDH1A1 (0.58) | ALDH1A1MAPTATMKDM4ETP53 | |
| SCHEMBL20593108 | 0.86 | ALDH1A1 (0.50) | ALDH1A1MAPTATMKDM4ETP53 | |
| SCHEMBL507149 | 0.85 | ALDH1A1 (0.58) | ALDH1A1MAPTATMKDM4ETP53 | |
| SCHEMBL30586439 | 0.85 | ALDH1A1 (0.58) | ALDH1A1MAPTATMKDM4ETP53 | |
| SCHEMBL29673226 | 0.85 | ALDH1A1 (0.58) | ALDH1A1MAPTATMKDM4ETP53 | |
| Iodide SCHEMBL20524052 | 0.84 | ALDH1A1 (0.56) | ALDH1A1MAPTATMKDM4ETP53 | |
| SCHEMBL25354572 | 0.82 | DAO (0.57) | ALDH1A1MAPTATMKDM4ETP53 | |
| SCHEMBL3846360 | 0.82 | DAO (0.54) | ALDH1A1MAPTATMKDM4ETP53 | |
| SCHEMBL252567 | 0.82 | DAO (0.54) | ALDH1A1MAPTATMKDM4ETP53 | |
| SCHEMBL6961498 | 0.82 | DAO (0.57) | ALDH1A1MAPTATMKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| EP-3893872-A1 | ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOF | Beta Pharma, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20210292334-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-09-23 | — | — | US | disclosed |
| US-20200286923-A1 | ARRAY ANTENNA, METHOD FOR PRODUCING SAME, AND LIQUID CRYSTAL ALIGNING AGENT FOR ARRAY ANTENNA | JSR CORPORATION (JP) | 2020-09-10 | — | — | US | disclosed |
| EP-3325497-B1 | QUINSTATIN COMPOUNDS | UNIV ARIZONA STATE (US) | 2020-09-02 | — | — | EP | disclosed |
| EP-3325497-B1 | QUINSTATIN COMPOUNDS | UNIV ARIZONA STATE (US) | 2020-09-02 | — | — | EP | disclosed |
| WO-2020124060-A1 | ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2019244939-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAME, AND PRODUCTION METHOD FOR SAID LIQUID CRYSTAL DISPLAY ELEMENT, AND DIAMINE COMPOUND | 日産化学株式会社 | 2019-12-26 | — | — | WO | disclosed |
| US-10435435-B2 | Quinstatin compounds | THE ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-10-08 | — | — | US | disclosed |
| WO-2017019489-A1 | QUINSTATIN COMPOUNDS | PETTIT GEORGE ROBERT (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017019489-A1 | QUINSTATIN COMPOUNDS | PETTIT GEORGE ROBERT (US) | 2017-02-02 | — | — | WO | disclosed |
| US-9260663-B2 | Liquid crystal composition, liquid crystal display, and method for producing liquid crystal display | JSR CORPORATION (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9260663-B2 | Liquid crystal composition, liquid crystal display, and method for producing liquid crystal display | JSR CORPORATION (JP) | 2016-02-16 | — | — | US | disclosed |
| US-20150092147-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY, AND METHOD FOR PRODUCING LIQUID CRYSTAL DISPLAY | JSR CORPORATION (JP) | 2015-04-02 | — | — | US | disclosed |
| US-20150092147-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY, AND METHOD FOR PRODUCING LIQUID CRYSTAL DISPLAY | JSR CORPORATION (JP) | 2015-04-02 | — | — | US | disclosed |
| EP-2571878-A1 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B]PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | Incozen Therapeutics Pvt. Ltd. (IN) | 2013-03-27 | — | — | EP | disclosed |
| WO-2012014898-A1 | LIQUID CRYSTAL ALIGNING AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学工業株式会社 (JP) | 2012-02-02 | — | — | WO | disclosed |
| WO-2011145035-A1 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | INDIAN INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011132751-A1 | LIQUID-CRYSTAL ALIGNMENT AGENT, LIQUID-CRYSTAL ALIGNMENT FILM, AND LIQUID-CRYSTAL DISPLAY ELEMENT | 日産化学工業株式会社 (JP) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | ALDH1A1 571/4885MAPT 3868/4885ATM 1124/4885 |
| US-10435435-B2 | Quinstatin compounds | QTRT1, COQ8A, QPCT | ALDH1A1 4656/4885MAPT 899/4885ATM 1878/4885 |
| US-20210292334-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | ALDH1A1 571/4885MAPT 3868/4885ATM 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.